Funding opportunities for FY19–DOD Breast Cancer Research Program

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The FY19 Defense Appropriation provides $130 million to the Department of Defense Breast Cancer Research Program to support innovative, high-impact research with clinical relevance that will accelerate progress to end breast cancer for Service members, Veterans, and the general public.

FY19 BCRP Program Announcements and General Application Instructions for the following award mechanisms are posted on the Grants.gov website.

Applications submitted to the FY19 BCRP must address one or more of the following overarching challenges:

  • Prevent breast cancer (primary prevention)

  • Identify determinants of breast cancer initiation, risk, or susceptibility

  • Distinguish deadly from non-deadly breast cancers

  • Conquer the problems of overdiagnosis and overtreatment

  • Identify what drives breast cancer growth; determine how to stop it

  • Identify why some breast cancers become metastatic

  • Determine why/how breast cancer cells lie dormant for years and then re-emerge; determine how to prevent lethal recurrence

  • Revolutionize treatment regimens by replacing them with ones that are more effective, less toxic, and impact survival

  • Eliminate the mortality associated with metastatic breast cancer

https://cdmrp.army.mil/funding/bcrp

Table of Contents

YOU MAY BE INTERESTED IN

Just consider for a minute if this was the first year of running your lab, if you were on the job market as a physician or scientist right now, if you were a resident contemplating a career in cancer research after fellowship, if you were a graduate student or postdoc, if you were an undergraduate or a technician who was looking toward graduate school.
The immune system can be a powerful tool to control cancer. Immune cells within our body detect cancer cells and release payloads that kill them. Transformative science in the last decade has led to the development of therapies that enhance the ability of our immune cells to carry out this function. These therapies, including checkpoint blockade and CAR-T cells, have been lifesaving for many patients that before had untreatable cancer. But, sadly, a majority of patients with advanced solid tumors still succumb to their disease. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login